Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
复制标题
DOI：
10.1093/cvr/cvaa222
复制
发表时间：
2020-09-01
影响因子：
10.8
通讯作者：
Thum, Thomas
中科院分区：
文献类型：
--
作者：
Tocchetti, Carlo Gabriele;Ameri, Pietro;Thum, Thomas
在西方国家，心血管（CV）疾病和癌症是老龄化人口的主要死亡原因。最近的流行病学数据表明，癌症在患有流行或偶发CV疾病的患者中更常见，特别是心力衰竭（HF）。事实上，在HF和癌症之间的共同风险因素和机制方面存在紧密联系。由抗癌治疗诱导的HF已被广泛研究，主要集中在抗肿瘤治疗对心肌细胞的毒性作用上。在这个心脏肿瘤学更新中，ESC心肌功能和心脏细胞生物学工作组的成员讨论了通过心肌细胞可能参与但不是中心的途径将心功能不全和癌症相互联系的新证据。特别是，心脏基质细胞（内皮细胞和成纤维细胞）和炎症细胞的多重作用被强调。此外，肠道微生物群被描述为HF和癌症之间的十字路口的新参与者。最后，非编码RNA在肿瘤学中的作用也得到了解决。所有这些见解预计将推动肿瘤学领域的额外研究工作。
In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.